The present invention relates to a compound for treating fungal disease, wherein said compound provide target-specific inhibition of fungal adhesion, biofilm formation, and filamentation without affecting their growth, at very low concentration. The compound of the present invention is selected from FDA approved drugs Cangrelor. Further, the present invention provides a composition comprising compound of the present invention and a pharmaceutically acceptable carrier. Further, the present invention provides a method of treating fungal infections using the compound and/or composition of the present invention. Furthermore, uses of the compound and/or composition is also being provided in the present disclosure.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
An apparatus for automatic discriminating and reckoning of peags, of different denominations, is disclosed. Said apparatus broadly comprises: an at least a conveying member (11); an at least a feeding member (12); an at least a smoothening member (18); an at least a pick and place member (13); a first receptacle (16); a second receptacle (17); an at least an object detecting member (14); an at least a control member (15); and a displaying member. Method of working of said apparatus is also disclosed. The disclosed apparatus may be implemented, in various environments, including, but not limited to: temples. The disclosed apparatus offers at least the following advantages: is efficient; is accurate; saves time; reduces manpower, thereby, reducing costs; and reduces redundancy errors.
The present disclosure relates to V and F-codoped cobalt hydroxide nanowires electrocatalysts V—Co(OH)2 comprises vanadium (V) at less stable 4+ oxidation state and fluoride (F) ions codoped directly on carbon cloth electrode. The V—Co(OH)2 produces excellent oxygen evolution reaction (OER) activity in alkaline conditions. The present disclosure also relates to a method of fabrication of the V and F-codoped cobalt hydroxide nanowires electrocatalysts V—Co(OH)2 comprising vanadium (V) at less stable 4+ oxidation state and fluoride (F) ions codoped directly on carbon cloth electrode by hydrothermal reaction.
C25B 11/091 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé d’au moins un élément catalytique et d’au moins un composé catalytiqueÉlectrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé de plusieurs éléments catalytiques ou composés catalytiques
C25B 11/02 - ÉlectrodesLeur fabrication non prévue ailleurs caractérisées par la configuration ou la forme
C25B 11/052 - Électrodes comportant un substrat et un ou plusieurs revêtements électro-catalytiques
C25B 11/056 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau du substrat ou du support constitué d'une matière textile ou non tissée
8444)(DMF)), and a method of preparing the same. More specifically, the present disclosure relates to a method of using said surface-coated porous ZnTPA MOF for selectively removing organic cationic dyes from an aqueous medium containing mix of dyes. Formula I
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance organique
An anti-infective agent for use in treatment of candidiasis is disclosed. A method of treating candidiasis is also disclosed. Said method comprises step of: administering an anti-infective agent, at a dosage that ranges between about 90 nM and about 200 nM. The disclosed anti-infective agent offers at least the advantage of inhibiting Candida species morphogenesis, at very low concentrations.
A61K 31/7034 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine
A nanocomposite for treating bacterial urinary tract infections is disclosed. Said nanocomposite broadly comprises: an about 10 mg/mL of zinc oxide nanoparticles; an about 2 mg/mL of type-A procyanidin; and methanol. Said zinc oxide nanoparticles are of sizes that range between about 20 nm and about 80 nm. A method of synthesising said nanocomposite is also disclosed. The disclosed nanocomposite and method offer at least the following synergistic advantages and effects: low MIC50 values; good bacterial biofilm inhibiting properties; eradicate pre-formed bacterial biofilms and dispersed bacterial cells; eradicate adhered bacterial cells; and superior safety profiles. The disclosed nanocomposite may be directly coated, onto catheters, for treating bacterial urinary tract infections. Alternatively, or in addition, it may also be part of a kit, for treating bacterial urinary tract infections.
C07D 311/62 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des substituants autres que des atomes d'oxygène ou de soufre en position 2 ou 4 avec des radicaux aryle liés en position 2 avec des atomes d'oxygène liés directement en position 3, p. ex. anthocyanidines
The present invention relates to metal organic framework (MOF) compounds. Specifically, the present invention relates to a metal organic framework compounds based on nickel, cobalt and copper metals and method of preparation thereof. The metal organic framework compounds of present invention exhibit enhanced electrocatalytic oxygen evolution reaction (OER) activity without using any additives or complimentary conducting materials.
B01J 31/16 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des complexes de coordination
B01J 31/28 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant en outre des composés métalliques inorganiques non prévus dans les groupes du groupe du platine, du cuivre ou du groupe du fer
The present invention relates to a compound for treating fungal disease, wherein said compound provide target-specific inhibition of fungal adhesion, biofilm formation, and filamentation without affecting their growth, at very low concentration. The compound of the present invention is selected from FDA approved drugs Cangrelor. Further, the present invention provides a composition comprising compound of the present invention and a pharmaceutically acceptable carrier. Further, the present invention provides a method of treating fungal infections using the compound and/or composition of the present invention. Furthermore, uses of the compound and/or composition is also being provided in the present disclosure.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
An aggregation induced emissive fluorophore (AIEgen) interconnected through nonconjugated spacer having a structural formula selected from: formulas (1), (2), or (3) wherein, (a); and X is (b), (c), (d), (e), (f), (g) or (h). The present disclosure further provides a process for preparing the AIEgen interconnected through nonconjugated spacer and applications thereof.
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
C07C 217/92 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes amino et des groupes hydroxy éthérifiés liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné ayant des groupes amino et des groupes hydroxy éthérifiés liés à des atomes de carbone de cycles aromatiques à six chaînons non condensés du même cycle aromatique à six chaînons non condensé l'atome d'azote d'au moins un des groupes amino étant lié de plus à un atome de carbone d'un cycle aromatique à six chaînons
brevets
